Site Map
CEL-SCI Home Page
o
About CEL-SCI
o
History
o
Mission and Values
o
Business Strategy
o
Corporate Overview
o
Privacy Policy
o
Corporate Headquarters
o
Company Code of Ethics
o
Management Team
o
Products
o
Cancer-Investigational Therapy Multikine
®
o
Introduction to Cancer Immunotherapy
o
Types of Biological Cancer Immunotherapy
Passive Immunotherapy
Active Immunotherapy
Investigational Combination Immunotherapy
o
Limitations of Current Immunotherapies
o
What is Investigational Multikine
® Therapy
?
Introduction to Investigational Therapy Multikine
®
(Leukocyte Interleukin, Injection)
Multikine
®
is a potential combination immunotherapy:
A new class of immunotherapy drugs
Clinical Trial Status Of Investigational Therapy Multikine
®
(Leukocyte Interleukin, Injection)”
Multikine
®
Phase III Clinical Trial Design
Multikine
®
Mechanism of Action
Potential Relevance of The Investigational Therapy Multikine
®
(Leukocyte Interleukin, Injection) to the Medical Community Responsible for Head and Neck Cancer Patients with Advanced Disease if Approved for Marketing by the FDA”
Head and Neck Cancer
Cigarette Smoking and Cancer: Q&A
o
Infectious Diseases-L.E.A.P.S.(TM)
o
Introduction and Overview
o
Summary of L.E.A.P.S.(TM) and CEL-1000 Collaborators
o
L.E.A.P.S.(TM) Scientific Backgrounder
o
Background on CEL-1000
o
Partnering Philosophy & Corporate Partners
o
Research & Clinical Trials
o
Investor Relations
o
SEC Filings
o
Stock Quotes
o
Scientific Publications/Presentations
o
News & Announcements
o
Press Releases
o
Sign Up for News
o
Careers
o
Job Postings
o
For Physicians
o
For Patients
Privacy Policy
News Releases
